GlassScriptPhysician profile
Edward George Butler
NPI 1528048139
$8,368.07
in general payments reported to CMS, 2019-2025
29 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 77% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $390 · 2021: $450 · 2022: $1,490 · 2023: $1,101 · 2024: $2,005 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,968 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.27 |
| Education | $141.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,097.61 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,077.61 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $946.04 | 2019-2025 | |
| Janssen Biotech, INC. | $715.98 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $646.13 | 2019-2025 | |
| Incyte Corporation | $633.92 | 2021-2025 | Opzelura |
| Amgen INC. | $630.38 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $403.33 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $392.63 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $294.96 | 2019-2024 | Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $203.07 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $198.88 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $194.31 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $188.10 | 2019-2023 | Targretin, Siliq |
| Ucb, INC. | $165.47 | 2019-2024 | Bimzelx |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $122.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Vyne Pharmaceuticals INC. | $58.31 | 2020-2021 | |
| Organogenesis INC. | $57.56 | 2024 | |
| Mayne Pharma Commercial LLC | $49.76 | 2023 | |
| Lilly USA, LLC | $44.48 | 2022-2025 | Ebglyss, Taltz |
| Aclaris Therapeutics, INC. | $30.28 | 2019 | |
| Sandoz INC. | $27.86 | 2023 | Hyrimoz |
| Organon LLC | $25.15 | 2025 | |
| Verrica Pharmaceuticals INC. | $22.51 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $17.42 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.99 | 2021 | |
| Dusa Pharmaceuticals, INC. | $14.10 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.